0001048477-24-000002.txt : 20240111
0001048477-24-000002.hdr.sgml : 20240111
20240111144039
ACCESSION NUMBER: 0001048477-24-000002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240108
FILED AS OF DATE: 20240111
DATE AS OF CHANGE: 20240111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 24528981
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
wk-form4_1705002030.xml
FORM 4
X0508
4
2024-01-08
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO STREET
SAN RAFAEL
CA
94901
1
0
0
0
1
Common Stock
2024-01-08
4
L
0
50
99.0518
A
425162
D
Common Stock
2024-01-09
4
M
0
10000
63.10
A
435162
D
Common Stock
2024-01-09
4
S
0
10000
98.19
D
425162
D
Common Stock
2024-01-10
4
M
0
10000
63.10
A
435162
D
Common Stock
2024-01-10
4
S
0
10000
96.38
D
425162
D
Common Stock
247333
I
Shares held by Jean-Jacques Bienaime Family Trust
Common Stock
100
I
Shares held as UTMA custodian for child 1
Common Stock
100
I
Shares held as UTMA custodian for child 2
Stock Option (Right to Buy Common Stock)
63.10
2024-01-09
4
M
0
10000
0
D
2014-12-04
2024-06-03
Common Stock
10000
171000
D
Stock Option (Right to Buy Common Stock)
63.10
2024-01-10
4
M
0
10000
0
D
2014-12-04
2024-06-03
Common Stock
10000
161000
D
The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Tae Sang Yoo, Attorney-in-Fact
2024-01-11